Amgen Inc  $238.03

Amgen, Inc. is a leading biotechnology company based in Thousand Oaks, California that specializes in the discovery, development, manufacture, and marketing of human therapeutics. The company boasts a comprehensive portfolio of marketed products, including Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), AVSOLA (infliximab-axxq), Evenity, LumaKras, Nplate, XGeva, and others. The company is dedicated to developing innovative human therapeutics that help treat serious illnesses in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience. With a team of 24,200 full-time employees, Amgen's market presence is strong, and its offerings are well-regarded by medical professionals and patients alike. Investors looking to track Amgen's share price and stock performance can keep a close eye on the market cap and stock price today, as well as stocks share price today and premarket movements. Additionally, those interested in Amgen's performance in Malaysia may want to monitor the price in Malaysia as well.